Log In
Print
BCIQ
Print
Print this Print this
 

solanezumab (LY2062430)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionMonoclonal antibody (mAb) binding to soluble beta amyloid
Molecular Target Beta amyloid
Mechanism of ActionAntibody
Latest Stage of DevelopmentPhase III
IndicationAlzheimer's disease (AD)
Partner

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today